Literature DB >> 35880974

Nonlinear mixed-effects models for HIV viral load trajectories before and after antiretroviral therapy interruption, incorporating left censoring.

Sihaoyu Gao1, Lang Wu1, Tingting Yu2, Roger Kouyos3,4, Huldrych F Günthard3,4, Rui Wang2,5.   

Abstract

Objectives: Characterizing features of the viral rebound trajectories and identifying host, virological, and immunological factors that are predictive of the viral rebound trajectories are central to HIV cure research. We investigate if key features of HIV viral decay and CD4 trajectories during antiretroviral therapy (ART) are associated with characteristics of HIV viral rebound following ART interruption.
Methods: Nonlinear mixed effect (NLME) models are used to model viral load trajectories before and following ART interruption, incorporating left censoring due to lower detection limits of viral load assays. A stochastic approximation EM (SAEM) algorithm is used for parameter estimation and inference. To circumvent the computational intensity associated with maximizing the joint likelihood, we propose an easy-to-implement three-step method.
Results: We evaluate the performance of the proposed method through simulation studies and apply it to data from the Zurich Primary HIV Infection Study. We find that some key features of viral load during ART (e.g., viral decay rate) are significantly associated with important characteristics of viral rebound following ART interruption (e.g., viral set point). Conclusions: The proposed three-step method works well. We have shown that key features of viral decay during ART may be associated with important features of viral rebound following ART interruption.
© 2022 Walter de Gruyter GmbH, Berlin/Boston.

Entities:  

Keywords:  HIV/AIDS studies; censoring; longitudinal data; stochastic approximation EM (SAEM) algorithm

Year:  2022        PMID: 35880974      PMCID: PMC9204768          DOI: 10.1515/scid-2021-0001

Source DB:  PubMed          Journal:  Stat Commun Infect Dis


  26 in total

1.  Nonlinear mixed effects models for repeated measures data.

Authors:  M L Lindstrom; D M Bates
Journal:  Biometrics       Date:  1990-09       Impact factor: 2.571

2.  The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies.

Authors:  Golnaz Namazi; Jesse M Fajnzylber; Evgenia Aga; Ronald J Bosch; Edward P Acosta; Radwa Sharaf; Wendy Hartogensis; Jeffrey M Jacobson; Elizabeth Connick; Paul Volberding; Daniel Skiest; David Margolis; Michael C Sneller; Susan J Little; Sara Gianella; Davey M Smith; Daniel R Kuritzkes; Roy M Gulick; John W Mellors; Vikram Mehraj; Rajesh T Gandhi; Ronald Mitsuyasu; Robert T Schooley; Keith Henry; Pablo Tebas; Steven G Deeks; Tae-Wook Chun; Ann C Collier; Jean-Pierre Routy; Frederick M Hecht; Bruce D Walker; Jonathan Z Li
Journal:  J Infect Dis       Date:  2018-11-05       Impact factor: 5.226

3.  Joint model-based clustering of nonlinear longitudinal trajectories and associated time-to-event data analysis, linked by latent class membership: with application to AIDS clinical studies.

Authors:  Yangxin Huang; Xiaosun Lu; Jiaqing Chen; Juan Liang; Miriam Zangmeister
Journal:  Lifetime Data Anal       Date:  2017-10-27       Impact factor: 1.588

4.  Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA.

Authors:  Sara Gianella; Viktor von Wyl; Marek Fischer; Barbara Niederoest; Manuel Battegay; Enos Bernasconi; Matthias Cavassini; Andri Rauch; Bernard Hirschel; Pietro Vernazza; Rainer Weber; Beda Joos; Huldrych F Günthard
Journal:  Antivir Ther       Date:  2011

5.  Factors affecting timing of antiretroviral treatment initiation based on monitoring CD4 counts.

Authors:  Farzad Noubary; Michael D Hughes
Journal:  J Acquir Immune Defic Syndr       Date:  2012-11-01       Impact factor: 3.731

6.  The replication-competent HIV-1 latent reservoir is primarily established near the time of therapy initiation.

Authors:  Melissa-Rose Abrahams; Sarah B Joseph; Nigel Garrett; Lynn Tyers; Matthew Moeser; Nancie Archin; Olivia D Council; David Matten; Shuntai Zhou; Deelan Doolabh; Colin Anthony; Nilu Goonetilleke; Salim Abdool Karim; David M Margolis; Sergei Kosakovsky Pond; Carolyn Williamson; Ronald Swanstrom
Journal:  Sci Transl Med       Date:  2019-10-09       Impact factor: 17.956

7.  Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel.

Authors:  Melanie A Thompson; Judith A Aberg; Pedro Cahn; Julio S G Montaner; Giuliano Rizzardini; Amalio Telenti; José M Gatell; Huldrych F Günthard; Scott M Hammer; Martin S Hirsch; Donna M Jacobsen; Peter Reiss; Douglas D Richman; Paul A Volberding; Patrick Yeni; Robert T Schooley
Journal:  JAMA       Date:  2010-07-21       Impact factor: 56.272

8.  Human immunodeficiency virus-specific CD8(+) T-cell responses do not predict viral growth and clearance rates during structured intermittent antiretroviral therapy.

Authors:  Annette Oxenius; Angela R McLean; Marek Fischer; David A Price; Sarah J Dawson; Roland Hafner; Christine Schneider; Helen Joller; Bernard Hirschel; Rodney E Phillips; Rainer Weber; Huldrych F Günthard
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

9.  Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV.

Authors:  Alison L Hill; Daniel I S Rosenbloom; Edward Goldstein; Emily Hanhauser; Daniel R Kuritzkes; Robert F Siliciano; Timothy J Henrich
Journal:  PLoS Pathog       Date:  2016-04-27       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.